Clarify the Role of Opzelura for Eczema

December 2021

Opzelura (ruxolitinib) 1.5% cream will be the first topical Janus kinase (JAK) inhibitor approved for mild to moderate eczema.

It suppresses cytokines to improve itching and inflammation.

Opzelura is thought to be safer than oral JAK inhibitors (Xeljanz, etc)...since it seems to have less than 10% systemic absorption.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

COVID-19 Educate About COVID-19 Vaccination for Kids 5 and Up
Vaccines Compare New Pneumococcal Vaccines to Prevnar 13 and Pneumovax 23
Eczema Clarify the Role of Opzelura for Eczema
Depression Consider Strategies for Seasonal Affective Disorder
Med Administration Teach Patients to Self-Inject Subcutaneous or IM Meds
Ophthalmology Watch for Tyrvaya Nasal Spray for Dry Eyes
Acne Help Patients Start and Stay on Isotretinoin for Acne
Sepsis Ensure Your Sepsis Protocols Include the Latest Evidence
Geriatrics Don’t Jump to Stimulants for Older Adults